Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies [0.03%]
allo-HSCT后供者淋巴细胞输注治疗髓系肿瘤患者的疗效分析
Maymona Abdelgamid,Naima J Hashi,Mehrdad Hefazi et al.
Maymona Abdelgamid et al.
Background: The efficacy of donor lymphocyte infusions (DLI) among various myeloid malignancies (particularly, genetic subtypes) and the optimal timing of DLI initiation remains unclear. ...
COVID-19 infection in patients with follicular lymphoma and related indolent B-cell lymphomas receiving anti-CD20 monoclonal antibody maintenance therapy [0.03%]
接受抗CD20单克隆抗体维持治疗的滤泡性淋巴瘤和相关惰性B细胞淋巴瘤患者的COVID-19感染
Shinto Kuniyoshi,Kohei Tanaka,Yu Akuzawa et al.
Shinto Kuniyoshi et al.
Introduction: Coronavirus disease 2019 (COVID-19) poses significant risks to immunocompromised individuals. Patients receiving maintenance therapy with anti-CD20 monoclonal antibodies for follicular lymphoma (FL) may be e...
Shared Care Offers an Effective Framework for Managing Tagraxofusp Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm [0.03%]
共享照护可为管理颗粒细胞树突状细胞肿瘤治疗提供有效框架
Alexander Ambinder,Thomas W LeBlanc,M Yair Levy et al.
Alexander Ambinder et al.
Tagraxofusp, a first-in-class CD123-targeted therapy, is the only approved treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Shared-care models enable coordination and care delivery between specialized cancer treatment cen...
Yajie Wang,Quan Rao,Yiming Ma et al.
Yajie Wang et al.
Objective： To analyze the clinical infusion effect of frozen-thawed-deglycerolized red blood cells (FTD-RBCs) and provide solutions for situations such as blood supply shortages. Methods： In this retrospective study, 280 patients receiving FT...
Treatment Decision-making for Individuals with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the United States [0.03%]
美国复发/难治慢性淋巴细胞白血病（CLL）患者的治疗决策流程
Catherine C Coombs,Thomas W LeBlanc,Katherine B Winfree et al.
Catherine C Coombs et al.
Background: As available treatment options for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) increase, treatment decisions become increasingly complex. This cross-sectional study evaluated patient and physi...
Diagnostic Pathways and Procedural Risk in Primary Central Nervous System Lymphoma: A Nationwide Analysis [0.03%]
原发中枢神经系统淋巴瘤的诊断途径和程序风险的全国范围分析
Kashif Qureshi,Sujai Arakali,Jose Anzueto et al.
Kashif Qureshi et al.
Introduction: Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy in which timely diagnosis is critical. While neurosurgical biopsy remains the gold standard, cerebrospinal fluid (CSF)-based diagno...
Prognostic factors and survival outcomes in ovarian lymphoma: a population-based analysis [0.03%]
卵巢淋巴瘤的预后因素和生存结果：基于人口的分析
Pierre Loap,Youlia Kirova
Pierre Loap
Background: Primary ovarian lymphoma represents a rare clinical entity accounting for 0.5% of non-Hodgkin lymphomas and 1.5% of ovarian neoplasms. Current literature is limited to small case series, with poorly defined pr...
Pia Raanani
Pia Raanani
Editorial
Acta haematologica. 2026 Apr 28:1-6. DOI:10.1159/000552225 2026
Persistent Splenomegaly is associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial [0.03%]
持续性脾大与坦桑尼亚镰状细胞贫血患儿发病率增加有关——SPHERE试验的二次分析结果
Emmanuela E Ambrose,George Tomlinson,Patrick S Ngoya et al.
Emmanuela E Ambrose et al.
Introduction: African children with sickle cell anemia (SCA) often have splenomegaly with recurrent cytopenias that complicate management, rather than the splenic atrophy typically observed in SCA. ...
Venetoclax-Based Regimens in Chronic Myelomonocytic Leukemia: A Systematic Review and Meta-Analysis [0.03%]
用于慢性粒单细胞白血病的Venetoclax方案的系统评价和meta分析
Mohammed Abdulgayoom,Mohammad S Afana,Leen Haj Saleh et al.
Mohammed Abdulgayoom et al.
Chronic myelomonocytic leukemia (CMML) is a biologically heterogeneous myelodysplastic/myeloproliferative neoplasm with limited disease-modifying options beyond hypomethylating agents (HMAs) and allogeneic hematopoietic stem cell transplant...